↓ Skip to main content

Dove Medical Press

Article Metrics

miR-136 targets MIEN1 and involves the metastasis of colon cancer by suppressing epithelial-to-mesenchymal transition

Overview of attention for article published in OncoTargets and therapy, December 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
28 Mendeley
Title
miR-136 targets MIEN1 and involves the metastasis of colon cancer by suppressing epithelial-to-mesenchymal transition
Published in
OncoTargets and therapy, December 2017
DOI 10.2147/ott.s113359
Pubmed ID
Authors

Haipeng Ren, Yuanling Qi, Xiaoyan Yin, Jianfeng Gao

Abstract

MIEN1 is a novel oncogene, and it involves tumor progression in various cancer types, including colon cancer. However, the definite molecular mechanisms of MIEN1 in colon cancer progression remain to be completely elucidated. In the present study, bioinformatics prediction showed that miR-136 could be an upstream regulator of MIEN1; a luciferase assay and Western blot assay revealed that miR-136 negatively regulates MIEN1 expression via directly targeting its 3'-untranslated region sequence. Moreover, a functional assay using wound healing and transwell invasion showed that overexpressed miR-136 inhibited cell migration and invasion, and overexpression of MIEN1 partly rescued the above-mentioned effects of miR-136 in colon cancer cells. Additionally, a clinical sample assay showed that miR-136 expression was generally downregulated in colon cancer tissue, which was inversely correlated with MIEN1 expression. Furthermore, we found that miR-136 suppressed the Akt/NF-κB signaling pathway and epithelial-to-mesenchymal transition in colon cancer. These results suggest that miR-136, as a tumor suppressor, acts in tumor metastasis by suppressing MIEN1 expression in colon cancer, providing a novel target for the treatment of colon cancer.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 28 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 6 21%
Student > Bachelor 5 18%
Other 3 11%
Librarian 2 7%
Professor 1 4%
Other 1 4%
Unknown 10 36%
Readers by discipline Count As %
Medicine and Dentistry 5 18%
Biochemistry, Genetics and Molecular Biology 4 14%
Social Sciences 3 11%
Immunology and Microbiology 1 4%
Psychology 1 4%
Other 3 11%
Unknown 11 39%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 December 2017.
All research outputs
#7,414,661
of 12,341,991 outputs
Outputs from OncoTargets and therapy
#406
of 1,507 outputs
Outputs of similar age
#179,425
of 347,188 outputs
Outputs of similar age from OncoTargets and therapy
#20
of 135 outputs
Altmetric has tracked 12,341,991 research outputs across all sources so far. This one is in the 37th percentile – i.e., 37% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,507 research outputs from this source. They receive a mean Attention Score of 2.4. This one has gotten more attention than average, scoring higher than 66% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 347,188 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 135 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 80% of its contemporaries.